Genenta Science (Nasdaq: GNTA), a leader in immuno-oncology, and Anemocyte, a prominent supplier of advanced therapy and nucleic acid solutions, have announced a strategic partnership aimed at advancing off-the-shelf lentiviral vector (LVV) plasmid DNA technology. This collaboration builds upon their existing successful relationship focused on plasmid DNA production.
The partnership will utilize Genenta”s established LVV plasmid DNA technology, which stems from the pioneering research of Professor Luigi Naldini, one of Genenta”s co-founders. This proven technology is set to enable Anemocyte to enhance its service offerings, providing clients with a consistent and high-quality source of materials ranging from research and development to good manufacturing practice (GMP) standards, covering both preclinical and commercial phases.
“Our expanded collaboration with Anemocyte represents a natural progression of a successful partnership in plasmid DNA manufacturing,” stated Pierluigi Paracchi, CEO of Genenta Science. “By making our clinically validated LVV plasmid DNA technology platform accessible to Anemocyte and its clients, we are facilitating the reliable and scalable development of advanced therapy programs across the sector.”
Marco Ferrari, CEO of Anemocyte, remarked, “Our collaboration with Genenta has already produced excellent results. By formalizing this new partnership, we are ensuring our clients have access to a robust, well-established platform for their advanced therapy programs, supported by Genenta”s extensive experience.”
This partnership signifies a key milestone for both organizations, emphasizing their joint commitment to delivering innovative and dependable solutions within the life sciences industry.
About Anemocyte: Anemocyte is a biotech manufacturing organization based in Italy, specializing in providing comprehensive development and manufacturing services. With over 25 years of expertise in innovative therapies and related starting materials, Anemocyte focuses on the research, development, and production of plasmid DNA and mRNA, offering solutions from R&D to GMP.
About Genenta Science: Genenta Science is a clinical-stage immuno-oncology firm developing proprietary hematopoietic stem cell therapies for various solid tumor cancers. Their leading candidate, TemferonTM, is engineered to facilitate the expression of immune-therapeutic payloads in the tumor microenvironment by myeloid cells derived from bone marrow, aiming for a durable and targeted therapeutic response. Genenta has successfully completed a Phase 1 trial for newly diagnosed glioblastoma multiforme patients with an unmethylated MGMT gene promoter, indicating potential for tumor microenvironment reprogramming and T cell response induction.
Statements in this press release may contain “forward-looking statements” as defined under the U.S. Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties. All statements not related to historical facts are considered forward-looking. These may include terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “project,” and similar terms.
For more information, please contact: Genenta Science Media, Tiziana Pollio, Mobile: +39 348 23 15 143, Email: [email protected]; Anemocyte Media, Telephone +39 0299372311, Email: [email protected], www.anemocyte.com.
